| John P Franchina, DO | |
|
400 W Main St, Suite 330, Babylon, NY 11702-3012 | |
| (631) 321-1239 | |
| (631) 422-0170 |
| Full Name | John P Franchina |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 24 Years |
| Location | 400 W Main St, Babylon, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457446569 | NPI | - | NPPES |
| 0136447 | Other | NY | GHI |
| 3450697 | Other | NY | AETNA |
| P3402911 | Other | NY | OXFORD |
| 346739P | Other | NY | HIP |
| 5C8276 | Other | NY | HEALTHNET |
| 230848 | Other | NY | HIP |
| 001GQ1 | Other | NY | BCBS |
| 7593543 | Other | NY | AETNA |
| 866E41 | Other | NY | BCBS |
| 3694573 | Other | NY | CIGNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 230848 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Hospital Medical Center | West islip, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optum Medical Care Pc | 9931013240 | 997 |
News Archive
A study of almost 400 former elite male athletes shows that former status as an elite athlete reduces the risk of developing type 2 diabetes in later life by 28%. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes, and is by Dr Merja Laine, University of Helsinki, Helsinki, Finland, and colleagues.
A new study from researchers at Columbia University Irving Medical Center found that binge drinking impairs working memory in the adolescent brain. The study, in mice, explains why teenagers who binge drink are 15 times more likely to become alcoholics during adulthood.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
› Verified 8 days ago
| Entity Name | Optum Medical Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982643003 PECOS PAC ID: 9931013240 Enrollment ID: O20031119000321 |
News Archive
A study of almost 400 former elite male athletes shows that former status as an elite athlete reduces the risk of developing type 2 diabetes in later life by 28%. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes, and is by Dr Merja Laine, University of Helsinki, Helsinki, Finland, and colleagues.
A new study from researchers at Columbia University Irving Medical Center found that binge drinking impairs working memory in the adolescent brain. The study, in mice, explains why teenagers who binge drink are 15 times more likely to become alcoholics during adulthood.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
› Verified 8 days ago
| Entity Name | Good Samaritan Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518901180 PECOS PAC ID: 5294639951 Enrollment ID: O20031124000491 |
News Archive
A study of almost 400 former elite male athletes shows that former status as an elite athlete reduces the risk of developing type 2 diabetes in later life by 28%. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes, and is by Dr Merja Laine, University of Helsinki, Helsinki, Finland, and colleagues.
A new study from researchers at Columbia University Irving Medical Center found that binge drinking impairs working memory in the adolescent brain. The study, in mice, explains why teenagers who binge drink are 15 times more likely to become alcoholics during adulthood.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
› Verified 8 days ago
| Entity Name | Prohealth Care Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275596280 PECOS PAC ID: 4486544186 Enrollment ID: O20040317000468 |
News Archive
A study of almost 400 former elite male athletes shows that former status as an elite athlete reduces the risk of developing type 2 diabetes in later life by 28%. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes, and is by Dr Merja Laine, University of Helsinki, Helsinki, Finland, and colleagues.
A new study from researchers at Columbia University Irving Medical Center found that binge drinking impairs working memory in the adolescent brain. The study, in mice, explains why teenagers who binge drink are 15 times more likely to become alcoholics during adulthood.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
› Verified 8 days ago
| Entity Name | Sun River Health Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568526838 PECOS PAC ID: 6608783568 Enrollment ID: O20040714000375 |
News Archive
A study of almost 400 former elite male athletes shows that former status as an elite athlete reduces the risk of developing type 2 diabetes in later life by 28%. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes, and is by Dr Merja Laine, University of Helsinki, Helsinki, Finland, and colleagues.
A new study from researchers at Columbia University Irving Medical Center found that binge drinking impairs working memory in the adolescent brain. The study, in mice, explains why teenagers who binge drink are 15 times more likely to become alcoholics during adulthood.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John P Franchina, DO 26 Railroad Ave, #217, Babylon, NY 11702-2204 Ph: (631) 321-1239 | John P Franchina, DO 400 W Main St, Suite 330, Babylon, NY 11702-3012 Ph: (631) 321-1239 |
News Archive
A study of almost 400 former elite male athletes shows that former status as an elite athlete reduces the risk of developing type 2 diabetes in later life by 28%. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes, and is by Dr Merja Laine, University of Helsinki, Helsinki, Finland, and colleagues.
A new study from researchers at Columbia University Irving Medical Center found that binge drinking impairs working memory in the adolescent brain. The study, in mice, explains why teenagers who binge drink are 15 times more likely to become alcoholics during adulthood.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
› Verified 8 days ago
Dr. John David Zimmerly, M.D. Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 454 Deer Park Ave, Babylon, NY 11702 Phone: 631-321-5440 |